[go: up one dir, main page]

JP5030366B2 - Composition for treatment of allergic diseases - Google Patents

Composition for treatment of allergic diseases Download PDF

Info

Publication number
JP5030366B2
JP5030366B2 JP2003154353A JP2003154353A JP5030366B2 JP 5030366 B2 JP5030366 B2 JP 5030366B2 JP 2003154353 A JP2003154353 A JP 2003154353A JP 2003154353 A JP2003154353 A JP 2003154353A JP 5030366 B2 JP5030366 B2 JP 5030366B2
Authority
JP
Japan
Prior art keywords
composition
extract
plant
sendangusa
hay fever
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003154353A
Other languages
Japanese (ja)
Other versions
JP2004352680A (en
Inventor
八束 吉田
Original Assignee
株式会社武蔵野免疫研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社武蔵野免疫研究所 filed Critical 株式会社武蔵野免疫研究所
Priority to JP2003154353A priority Critical patent/JP5030366B2/en
Publication of JP2004352680A publication Critical patent/JP2004352680A/en
Application granted granted Critical
Publication of JP5030366B2 publication Critical patent/JP5030366B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Description

【0001】
【発明の属する技術分野】
本発明はセンダングサ属植物抽出物を含むアレルギー性疾患の治療用組成物に関する。
【0002】
【従来の技術】
近年、アトピー性皮膚炎や花粉症等のアレルギー性疾患を患う患者数が増加している。特に日本の杉花粉症は昭和30年代から40年代に全国的に植林された杉が成木となって大量の花粉が飛散するようになり、併せてモータリゼーションの普及によって大気汚染が進んだことと相俟って蔓延し、実際、杉花粉が大量かつ高濃度に飛散する杉林に近い地域よりも、ある程度離れた大気汚染の激しい地域の方が花粉症が多いと言われており、今日では国民の3人に一人は花粉症であるとさえ言われるようになった。さらに妊娠中の母体がディーゼル車の排ガスを吸うと胎児が将来花粉症を起こしやすくなることがラットの実験で証明されている。これらのアレルギー性疾患は、個人によって発症の様相や程度が様々であり、本来個人の体質的なものが大きく、治療法は一般に対症的で根本的に治癒させることは困難である。また、アレルギー性疾患に従来用いられている抗ヒスタミン剤や抗アレルギー剤は眠気を催すなどの副作用が認められ、服用できない場合もある。また、アトピー性皮膚炎の炎症を抑制するためにしばしば処方される副腎皮質ホルモン系薬剤にも強い副作用が認められる。また、抗アレルギー剤の中には治療効果が奏されるまでに比較的長い期間を必要とするものもある。
一方、ビデンス・ピローサ等のセンダングサ属植物は昔から身近にあるハーブであり、干した地上部分を煎じたものが飲用に供されている。センダングサ属植物抽出物を含む化粧品については肌荒れを改善する効果などが報告されている(例えば、特許文献1参照)。また、センダングサ属植物抽出物に抗炎症性成分が含まれていることも報告されている(例えば、特許文献2参照)。
【0003】
【特許文献1】
特開2001−233727号公報
【特許文献2】
特開2003−73315号公報
【0004】
【発明が解決しようとする課題】
本発明は有効にアレルギー性疾患を治療するための組成物を提供することを目的とする。本発明はまた、副作用が少なく、かつ有効にアレルギー性疾患を治療するための組成物を提供することを目的とする。
【0005】
【課題を解決するための手段】
上記課題は、センダングサ属植物抽出物(センダングサ属植物にショウガ科植物を混合して抽出したものを除く)を含む組成物の服用により花粉症やアトピー性皮膚炎等のアレルギー性疾患の症状が改善されることが見出された。すなわち、本発明はセンダングサ属植物抽出物(センダングサ属植物にショウガ科植物を混合して抽出したものを除く)を含むアレルギー性疾患治療用組成物に関する。
また、本発明はアレルギー性疾患が花粉症である、センダングサ属植物抽出物を含むアレルギー性疾患治療用組成物に関する。さらに前記花粉症が杉花粉、ヒノキ花粉、セイタカアワダチソウ花粉、ブタクサ花粉及びイネ科植物花粉からなる群より選択される少なくとも一種に対する花粉症である、上記組成物に関する。
本発明はまた、アレルギー性疾患がアトピー性皮膚炎または接触性皮膚炎である、センダングサ属植物抽出物を含むアレルギー性疾患治療用組成物に関する。
本発明はまたセンダングサ属植物がビデンス・ピローサ類である、上記組成物に関する。さらに本発明は、センダングサ属植物抽出物の含有量(乾燥固形分)が0.01〜10質量%である上記組成物に関する。
【0006】
【発明の実施の形態】
本発明に使用されるセンダングサ属植物は、特開2001−178390号公報および特開2001−233727号公報に記載されるように、学名ではビデンス(Bidens)属と言われる一群の植物である。種類も多岐に亘り互いに交配するので変種も多く、植物学上も混乱が見られ、学名、和名、漢名、の対応も交錯していて同定することは極めて困難であるが、本発明で用いられるセンダングサ属植物は以下に掲げるものを包含する。
【0007】
Bidens pilosa L.(コセンダングサ、コシロノセンダングサ、咸豊草)
Bidens pilosa L. var. minor (Blume)Sherff (シロバナセンダングサ、シロノセンダングサ、コシロノセンダングサ、コセンダングサ、咸豊草)
Bidens pilosa L. var. bisetosa Ohtani et S.Suzuki(アワユキセンダングサ)
Bidens pilosa L. f. decumbens Scherff (ハイアワユキセンダングサ)
Bidens pilosa L. var. radiata Scherff (タチアワユキセンダングサ、ハイアワユキセンダングサを含むこともある)
Bidens pilosa L. var. radiata Schultz Bipontinus (シロノセンダングサ、オオバナノセンダングサ)
Bidens biternata Lour. Merrill et Sherff(センダングサ)
Bidens bipinnata L.(コバノセンダングサ、センダングサ)
Bidens cernua L.(ヤナギタウコギ)
Bidens frondosa L.(アメリカセンダングサ、セイタカタウコギ)
Bidens maximowicziana Oett(羽叶鬼針草)
Bidens parviflora Willd(ホソバノセンダングサ)
Bidens radiata Thuill. var. pinnatifida (Turcz.)Kitamura(エゾノタウコギ)
Bidens tripartita L.(タウコギ)
【0008】
上記センダングサ属植物の中で、特にビデンス・ピローサ(Bidens pilosa)類が好ましい。
上記センダングサ属植物は通常、生の植物を天日乾燥または熱風(例えば70〜80℃)乾燥したもの、又は蒸気で、例えば1時間〜1時間半程度蒸した後、乾燥したものを使用してもよい。
上記センダングサ属植物の使用部位は、根、地上部(茎、葉、花等)又は全草何れの部位を用いてもよい。特に、葉及び茎の部分を使用することが効力の点において好ましい。
【0009】
また、本発明の組成物にはさらに酸化防止の目的で他の成分または植物を加えてもよい。他の成分または植物として具体的にはアセロラ抽出物またはアセロラ等の柑橘類の果実や茶葉などが挙げられる。このような成分または植物を添加する場合には、センダングサ属植物に添加して抽出してもよく、また、抽出後に添加してもよい。このような成分は、センダングサ属植物乾燥重量に対して、乾燥重量基準で1〜50質量%添加してもよい。
ただし、本発明においてセンダングサ属植物抽出物は、センダングサ属植物にショウガ科植物を混合して抽出溶媒等により抽出したものを除く。
【0010】
本発明の組成物に含まれるセンダングサ属植物の抽出物を得る方法の一つの実施態様を示すと、上述したようにセンダングサ属植物を乾燥したもの又は蒸気で蒸した後乾燥したものに対して、乾燥または蒸気で蒸した後乾燥し、常温又は加温下に、溶媒を添加して抽出する。抽出方法としては例えば、浸漬して静置、またはソックスレー抽出器等の抽出器具を用いて抽出物を得ることもできる。
【0011】
抽出に使用される溶媒の例としては、水、メタノール、エタノール、プロパノール、ブタノール、エチレングリコール、プロパンジオール、ブタンジオール、グリセリン等のアルコール類、並びにこれらの含水物、アセトン、エチルメチルケトン、クロロホルム、塩化メチレン及び酢酸エチル、並びにそれらの含水物を用いてもよい。また、上記溶媒を二種以上含む混合物であってもよい。溶媒の添加量は、例えば用いる植物の合計乾燥重量1kgに対して1L〜100L程度使用することができる。
抽出時の温度は、通常、室温〜沸点程度で行うことができる。また、抽出時間は、温度や溶媒にもよるが、室温〜沸点程度で抽出を行う場合には、1〜300時間程度の範囲にわたって行うことができる。
【0012】
抽出液は必要により溶媒を留去濃縮して濃縮物または固形物(乾燥物)としてもよい。濃縮物として使用する場合、濃度を調整した後そのまま用いてもよい。また、抽出物は、脱色、不要物除去のため活性炭処理、HP20等の樹脂処理、低温放置、瀘過等の処理を施してから用いてもよい。さらに当該抽出物を適当な分離手段、例えばゲル瀘過法やシリカゲルカラムクロマト法、又は逆相若しくは順相の高速液体クロマト法により活性の高い画分を分画して用いることもできる。本発明においてセンダングサ属植物抽出物にはこのような分画物も含むものとする。得られた抽出物はそのまま、あるいは濃縮物または固形物(例えば粉末)としてもよい。また使用目的に応じて他の成分を混合してもよい。
本発明の組成物中におけるセンダングサ属植物抽出物の含有量は、乾燥固形分重量として、0.01〜10質量%程度含まれることが好ましく、0.1〜10質量%含まれることがさらに好ましい。ただし、活性の高い分画物を用いる場合にはその活性に応じた量を用いることができる。
【0013】
本発明のセンダングサ属植物抽出物を含む組成物は、アレルギー性疾患の治療において用いることができる。アレルギー性疾患の例としては花粉症が挙げられる。さらに花粉症としては、杉花粉、ヒノキ花粉、セイタカアワダチソウ花粉、ブタクサ花粉及びイネ科植物花粉からなる群より選択される少なくとも一種に対する花粉症が挙げられる。
本発明のセンダングサ属植物抽出物を含む組成物を花粉症治療用組成物として用いる場合、いずれの形態で用いてもよく、抽出液、または抽出物を水等で希釈または溶解した液状物として、または、粉末、錠剤等の固形物として経口投与してもよい。錠剤等に成型する場合には従来知られている担体、倍散剤、崩壊剤、滑沢剤等を用いることができる。
花粉症治療用組成物として用いる場合、成人について一日あたり、センダングサ属植物抽出物(乾燥固形分)に換算して0.001〜1g/kg(体重)程度投与することが好ましい。
【0014】
また、アレルギー性疾患の例として、アトピー性皮膚炎または接触性皮膚炎が挙げられる。アトピー性皮膚炎及び接触性皮膚炎はいずれの物質に対するものであってもよく、特に限定されない。
本発明のセンダングサ属植物抽出物を含む組成物をアトピー性皮膚炎または接触性皮膚炎治療用組成物として用いる場合、いずれの形態で用いてもよく、花粉症治療用組成物として用いる場合と同様に、抽出液、または抽出物を水等で希釈または溶解した液状物として、または、粉末、錠剤等の固形物として経口投与してもよい。また、クリーム、軟膏、パッチ等の外用剤として用いてもよい。
アトピー性皮膚炎または接触性皮膚炎治療用組成物として用いる場合、経口投与する場合には、成人について一日あたり、センダングサ属植物抽出物(乾燥固形分)に換算して0.001〜1g/kg(体重)程度投与することが好ましい。外用剤の場合には、0.001質量%〜10質量%程度含有する外用剤を使用することが好ましい。
【0015】
〔実施例〕
以下に本発明の実施例について述べる。
実施例1(花粉症治療用組成物)
・ビデンスピローサ抽出物の製造:ビデンスピローサ加工乾燥物(特開2001−178390の方法により加工した乾燥物)10kgに100Lの常水を加え、一度煮沸後時々攪拌しながら2時間、95〜100℃に保って抽出し、加圧ろ過して清澄した抽出液を減圧濃縮し、再度5Lの水に溶解して85℃、30分加熱処理を行い、乳糖600gを加えて均一に溶解し噴霧乾燥して3.2kgのエキス粉末を得た。
・薬剤の調製:上記エキス粉末全量に崩壊剤として微結晶セルロース300gと蔗糖脂肪酸エステル150gを加え、局方エタノールで湿潤させ、0.7mmΦのスクリーンを通して顆粒化し、打錠して250mgの錠子とした。
【0016】
杉花粉症患者9名(成人男女8名及び小児1名)について上記錠剤の効果を試験した。各患者は例年杉花粉の飛散する時期にくしゃみ、鼻水、目のかゆみ等の症状を発症する患者であり、医療機関に受診して医師の指導で抗アレルギー剤を服用し、マスクの着用など症状を和らげる各種の措置を講じてきたが多かれ少なかれ上記症状を呈していた患者である。
この9名の患者に対し、医者の薬を止めてもらい、本発明の錠剤を1日3回、1回3錠、食間(午前と午後と就寝前)に投与し、約1ヶ月間継続して、患者について観察を行った。
9名のうち8人が投与5日後に症状が全くなくなった。また、1名(No.8)の患者は本発明の錠剤の服用を2日間忘れたところ症状が再発した。しかし服用を再開すると服用再開日翌日から症状が消退した。1名(No.9)は各種の症状が軽減したものの1ヶ月を経てまだ完治に至っていない。また、No.8以外の8名はその後1日量を3錠/回に減らして服用を継続しているが2ヶ月以上再発していない。
また、全員について副作用と思われる症状は全く認められなかった。
【0017】

Figure 0005030366
【0018】
実施例2(全身アトピー性皮膚炎治療用組成物)
実施例1と同様にビデンス・ピローサ抽出物を製造し、その抽出物を使用して実施例1と同様に250mgの錠剤を作成した。
全身アトピー性皮膚炎患者3名(成人男女3名)について上記錠剤の効果を示した。各患者は数年来、全身アトピー性皮膚炎(皮膚の柔らかい部位に多発している)で、いずれも皮膚科医を受診している。治療は外用薬剤のみで主に亜鉛華と弱〜中程度のステロイド軟膏の合剤を使用しているが、局所的に軽快してもまた他の部位に発症するという状態を繰り返している患者である。
この3名の患者に対し、医者の薬を止めてもらい、本発明の錠剤を1日3回、1回3錠、食間(午前と午後と就寝前)に投与し、約1ヶ月間継続して、患者について観察を行った。
以下に示すように、3名とも服用開始後1週間〜2週間以内で症状の軽減が認められ、1カ月後には症状の沈静化が認められた。その後2ヶ月以上にわたって服用を継続しているが、再発の症状は認められない。
また、全員について副作用と思われる症状は全く認められなかった。
【0019】
Figure 0005030366
【発明の効果】
本発明のセンダングサ属植物抽出物を含む組成物を投与することにより、花粉症及びアトピー性皮膚炎等のアレルギー性疾患を、副作用を生ずることなく有効に治療することができる。[0001]
BACKGROUND OF THE INVENTION
The present invention relates to a composition for treating allergic diseases comprising a plant extract of Sendangusa.
[0002]
[Prior art]
In recent years, the number of patients suffering from allergic diseases such as atopic dermatitis and hay fever is increasing. In particular, Japanese cedar pollinosis is caused by cedars planted nationwide in the Showa 30s and 1940s, becoming a mature tree, and a large amount of pollen being scattered. It is said that there are more hay fever in areas where air pollution is far away, rather than areas close to cedar forest where cedar pollen is scattered in large quantities and in high concentrations. One of the three was even said to have hay fever. Furthermore, rat experiments have shown that if a pregnant mother breathes exhaust gas from a diesel vehicle, the fetus is more likely to develop hay fever in the future. These allergic diseases vary in appearance and degree from individual to individual, and are inherently large in physical constitution, and treatment methods are generally symptomatic and difficult to cure fundamentally. Further, antihistamines and antiallergic agents conventionally used for allergic diseases have side effects such as drowsiness and may not be taken. Adverse corticosteroids often prescribed to suppress inflammation of atopic dermatitis also have strong side effects. Some antiallergic agents require a relatively long period of time before a therapeutic effect is achieved.
On the other hand, Sendangusa plants such as Bidence Pirosa are herbs that have been around for a long time, and decocted dried ground parts are used for drinking. As for cosmetics containing the plant extract of the genus Sendangusa, an effect of improving rough skin has been reported (for example, see Patent Document 1). In addition, it has also been reported that an anti-inflammatory component is contained in the Sendangusa plant extract (see, for example, Patent Document 2).
[0003]
[Patent Document 1]
JP 2001-233727 A [Patent Document 2]
JP 2003-73315 A
[Problems to be solved by the invention]
An object of this invention is to provide the composition for treating allergic disease effectively. It is another object of the present invention to provide a composition for effectively treating allergic diseases with few side effects.
[0005]
[Means for Solving the Problems]
The above problem is that symptoms of allergic diseases such as hay fever and atopic dermatitis are improved by taking a composition containing Sendangusa plant extracts (excluding those extracted by mixing Ginger plants with Sendangusa plants) It was found that That is, the present invention relates to a composition for treating allergic diseases comprising a Sendangusa plant extract (excluding a mixture of Sendangusa plants and a ginger family plant extracted).
The present invention also relates to a composition for treating an allergic disease comprising a Sendangusa plant extract, wherein the allergic disease is hay fever. Further, the present invention relates to the above composition, wherein the hay fever is hay fever for at least one selected from the group consisting of cedar pollen, cypress pollen, stag beetle pollen, ragweed pollen and grass pollen.
The present invention also relates to a composition for treating an allergic disease comprising a Sendangusa plant extract, wherein the allergic disease is atopic dermatitis or contact dermatitis.
The present invention also relates to the above composition, wherein the plant of the genus Sendangusa is a Bidence Pirosa. Furthermore, this invention relates to the said composition whose content (dry solid content) of a Sendangusa genus plant extract is 0.01-10 mass%.
[0006]
DETAILED DESCRIPTION OF THE INVENTION
As described in Japanese Patent Application Laid-Open Nos. 2001-178390 and 2001-233727, the plants belonging to the genus Sendangsa used in the present invention are a group of plants referred to by the genus Bidens. There are many varieties because they cross each other in a wide variety, and there is confusion in botany, and it is extremely difficult to identify because the correspondence between scientific names, Japanese names, and Han names is also mixed. The Sendangsa plants used include the following:
[0007]
Bidens pilosa L. (Kosendangusa, Koshirono Sendangusa, Sakai Toyokusa)
Bidens pilosa L. var. Minor (Blume) Sherff (Shirobanasendangusa, Shironosendangusa, Koshironosendangsa, Kosendangsa, Sengyogusa)
Bidens pilosa L. var. Bisetosa Ohtani et S. Suzuki
Bidens pilosa L. f. Decumbens Scherff (high millet snow Bidens)
Bidens pilosa L. var. Radiata Scherff (may also include Tachiawayukisendangusa, Hiawayukisendangusa)
Bidens pilosa L. var. Radiata Schultz Bipontinus (Shironosendangusa)
Bidens biternata Lour. Merrill et Sherff (Sendangsa)
Bidens bipinnata L. (Kobano Sendangsa, Sendangsa)
Bidens cernua L.
Bidens frondosa L. (American Sendangsa, Seitakatakogi)
Bidens maximowicziana Oett
Bidens parviflora Willd
Bidens radiata Thuill. Var. Pinnatifida ( Turcz.) Kitamura ( Ezonotaukogi)
Bidens tripartita L.
[0008]
Among the above-mentioned plants of the genus Sendangsa, Bidens pilosa is particularly preferable.
The above-mentioned Sendangsa plant usually uses a raw plant obtained by drying in the sun or hot air (for example, 70 to 80 ° C.), or steaming, for example, steaming for about 1 hour to 1 and a half hours, and then drying the plant. Also good.
The use part of the above-mentioned Sendangsa plant may be any part of the root, the above-ground part (stem, leaf, flower, etc.) or the whole plant. In particular, the use of leaf and stem portions is preferred in terms of efficacy.
[0009]
Moreover, you may add another component or a plant to the composition of this invention for the purpose of antioxidant. Specific examples of other components or plants include acerola extract or citrus fruits such as acerola and tea leaves. When such a component or plant is added, it may be extracted by adding to the plant of the genus Sendangusa, or may be added after extraction. Such a component may be added in an amount of 1 to 50% by mass based on the dry weight with respect to the dry weight of the Sendangusa plant.
However, in the present invention, the Sendangusa genus plant extract excludes those obtained by mixing a Ginger family plant with the Sendangsa genus plant and extracting it with an extraction solvent or the like.
[0010]
One embodiment of the method for obtaining the extract of the plant belonging to the genus Sendanga included in the composition of the present invention is as follows. As described above, the plant of the genus Sendangsa is dried or steamed with steam and dried. It is dried or steamed and then dried, and extracted by adding a solvent at room temperature or under heating. As an extraction method, for example, it is possible to obtain an extract by immersing and standing, or using an extraction device such as a Soxhlet extractor.
[0011]
Examples of solvents used for extraction include water, methanol, ethanol, propanol, butanol, ethylene glycol, propanediol, butanediol, glycerin and other alcohols, and their hydrates, acetone, ethyl methyl ketone, chloroform, Methylene chloride and ethyl acetate and their hydrates may be used. Moreover, the mixture containing 2 or more types of the said solvent may be sufficient. The amount of the solvent added can be, for example, about 1 L to 100 L with respect to 1 kg of the total dry weight of the plant to be used.
The temperature at the time of extraction can be normally performed at room temperature to about the boiling point. The extraction time depends on the temperature and the solvent, but when extraction is performed at room temperature to about boiling point, it can be performed over a range of about 1 to 300 hours.
[0012]
The extract may be concentrated or solid (dry product) by distilling off the solvent if necessary. When used as a concentrate, it may be used as it is after the concentration is adjusted. Further, the extract may be used after being subjected to treatment such as activated carbon treatment, resin treatment such as HP20, low-temperature standing, filtration, etc. for decolorization and removal of unnecessary substances. Further, the extract can be used by fractionating a highly active fraction by an appropriate separation means such as a gel filtration method, a silica gel column chromatography method, or a reversed phase or normal phase high performance liquid chromatography method. In the present invention, the Sendangusa plant extract includes such a fraction. The obtained extract may be used as it is, or as a concentrate or a solid (eg, powder). Further, other components may be mixed according to the purpose of use.
The content of the Sendangusa plant extract in the composition of the present invention is preferably about 0.01 to 10% by mass, and more preferably 0.1 to 10% by mass as the dry solid content. However, when a highly active fraction is used, an amount corresponding to the activity can be used.
[0013]
The composition containing the Sendangusa plant extract of the present invention can be used in the treatment of allergic diseases. An example of an allergic disease is hay fever. Furthermore, examples of hay fever include hay fever for at least one selected from the group consisting of cedar pollen, cypress pollen, stag beetle pollen, ragweed pollen, and grass pollen.
When the composition containing the plant extract of the genus Sendanga of the present invention is used as a composition for treating hay fever, it may be used in any form, as an extract or a liquid obtained by diluting or dissolving the extract with water, Alternatively, it may be orally administered as a solid such as a powder or a tablet. In the case of molding into tablets or the like, conventionally known carriers, powders, disintegrants, lubricants and the like can be used.
When used as a composition for treating hay fever, it is preferable to administer about 0.001 to 1 g / kg (body weight) per day for an adult in terms of a Sendangsa plant extract (dry solid content).
[0014]
Examples of allergic diseases include atopic dermatitis and contact dermatitis. Atopic dermatitis and contact dermatitis may be for any substance and are not particularly limited.
When the composition containing the plant extract of the genus Sendanga of the present invention is used as a composition for treating atopic dermatitis or contact dermatitis, it may be used in any form and is the same as when used as a composition for treating hay fever. In addition, the extract or the extract may be orally administered as a liquid obtained by diluting or dissolving with water or the like, or as a solid such as a powder or a tablet. Moreover, you may use as external preparations, such as cream, ointment, and a patch.
When used as a composition for the treatment of atopic dermatitis or contact dermatitis, when orally administered, 0.001 to 1 g / kg per day for adults (converted to Sendangsa plant extract (dry solids)) It is preferable to administer about (weight). In the case of an external preparation, it is preferable to use an external preparation containing about 0.001% by mass to 10% by mass.
[0015]
〔Example〕
Examples of the present invention will be described below.
Example 1 (Composition for hay fever treatment)
-Manufacture of bidenspirosa extract: 100L of normal water was added to 10kg of dried bidenspirosa processed dried product (dried product processed by the method of JP-A-2001-178390), and once boiled, kept at 95-100 ° C for 2 hours with occasional stirring. Extracted, filtered under pressure and concentrated under reduced pressure, dissolved again in 5 L of water, heat-treated at 85 ° C. for 30 minutes, added uniformly with 600 g of lactose, spray-dried and then dried by 3.2. kg extract powder was obtained.
-Preparation of drug: 300 g microcrystalline cellulose and 150 g sucrose fatty acid ester as disintegrants were added to the total amount of the above extract powder, moistened with pharmacopeia ethanol, granulated through a 0.7 mmΦ screen, and tableted into a 250 mg tablet. .
[0016]
The effect of the tablet was tested on 9 patients with cedar pollinosis (8 adult men and women and 1 child). Each patient usually develops symptoms such as sneezing, runny nose, itchy eyes, etc. at the time when cedar pollen is scattered every year, visit a medical institution, take antiallergic agents under the guidance of a doctor, and wear masks A patient who has taken various measures to relieve her symptoms but has more or less the above symptoms.
The nine patients were given a doctor's medication and the tablets of the present invention were administered three times a day, three tablets once a day between meals (morning, afternoon and before going to bed) and continued for about one month. The patient was observed.
Eight out of nine patients were completely free of symptoms 5 days after administration. In addition, one patient (No. 8) forgot to take the tablet of the present invention for 2 days, and his symptoms recurred. However, the symptoms disappeared from the day after the resumed dose when the dose was resumed. Although one person (No. 9) has alleviated various symptoms, it has not yet been completely cured after one month. No. Eight patients other than 8 have continued to take the daily dose to 3 tablets / dose, but have not relapsed for more than 2 months.
In addition, no symptoms that seemed to be side effects were observed at all.
[0017]
Figure 0005030366
[0018]
Example 2 (Composition for treating systemic atopic dermatitis)
A Bidence Pilosa extract was produced in the same manner as in Example 1, and a 250 mg tablet was prepared in the same manner as in Example 1 using the extract.
The effect of the tablet was demonstrated on 3 patients with systemic atopic dermatitis (3 adult men and women). Each patient has been suffering from systemic atopic dermatitis (which frequently occurs in soft areas of the skin) for several years, and all have been consulting a dermatologist. Treatment is for external use only, mainly zinc oxide and weak to moderate steroid ointment combination, but patients with repeated symptoms that develop locally but also develop elsewhere is there.
The three patients were given a doctor's medication and the tablet of the present invention was administered three times a day, three tablets once a day between the meals (morning, afternoon and before going to bed) and continued for about one month. The patient was observed.
As shown below, all the three patients showed relief of symptoms within 1 to 2 weeks after the start of administration, and symptom calming was observed one month later. The patient has been taking the drug for more than 2 months, but no signs of recurrence are observed.
In addition, no symptoms that seemed to be side effects were observed at all.
[0019]
Figure 0005030366
【Effect of the invention】
By administering the composition containing the plant extract of the genus Sendanga of the present invention, allergic diseases such as hay fever and atopic dermatitis can be effectively treated without causing side effects.

Claims (2)

ビデンス・ピローサ抽出物(ビデンス・ピローサにショウガ科植物を混合して抽出したものを除く)を含み、ビデンス・ピローサ抽出物が、水を溶媒として抽出された抽出物である花粉症治療用組成物。A composition for treating hay fever , comprising a Bidence Pirosa extract ( excluding a Bidence Pirosa mixed with a ginger plant extract) , wherein the Bidence Pirosa extract is extracted using water as a solvent . 花粉症が杉花粉に対する花粉症である、請求項1記載の組成物。Hay fever is pollinosis against the cedar pollen composition of claim 1.
JP2003154353A 2003-05-30 2003-05-30 Composition for treatment of allergic diseases Expired - Lifetime JP5030366B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003154353A JP5030366B2 (en) 2003-05-30 2003-05-30 Composition for treatment of allergic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003154353A JP5030366B2 (en) 2003-05-30 2003-05-30 Composition for treatment of allergic diseases

Publications (2)

Publication Number Publication Date
JP2004352680A JP2004352680A (en) 2004-12-16
JP5030366B2 true JP5030366B2 (en) 2012-09-19

Family

ID=34049033

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003154353A Expired - Lifetime JP5030366B2 (en) 2003-05-30 2003-05-30 Composition for treatment of allergic diseases

Country Status (1)

Country Link
JP (1) JP5030366B2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007197380A (en) * 2006-01-27 2007-08-09 Musashino Meneki Kenkyusho:Kk Antihistamine containing enzyme-treated products of the genus Sendungusa
US7763285B2 (en) * 2007-02-12 2010-07-27 Academia Sinica Polyacetylenic compounds
DE102015102020A1 (en) * 2015-02-12 2016-08-18 Renate Wilmanowicz Immunologically active phytogen mixture and its use in prevention and in a process for the treatment of efflorescences
US20180201794A1 (en) * 2017-01-19 2018-07-19 The Boeing Company Sustainable additives for anti-corrosion coatings for substrates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0390036A (en) * 1989-08-31 1991-04-16 Daicel Chem Ind Ltd Vaccine for pollinosis of sugi and hinoki
JP3769036B2 (en) * 1994-08-01 2006-04-19 ポーラ化成工業株式会社 Inhibitor against excessive human body
JP2001233889A (en) * 2000-02-21 2001-08-28 Nissan Chem Ind Ltd New flavonoid glycoside and composition containing the same
JP2001233888A (en) * 2000-02-25 2001-08-28 Nissan Chem Ind Ltd New polyacetylene glycoside and composition containing the same
JP5495466B2 (en) * 2001-01-09 2014-05-21 株式会社武蔵野免疫研究所 Blood circulation improving agent
JP4864252B2 (en) * 2001-09-04 2012-02-01 株式会社武蔵野免疫研究所 Anti-inflammatory plant component

Also Published As

Publication number Publication date
JP2004352680A (en) 2004-12-16

Similar Documents

Publication Publication Date Title
AU733601B2 (en) Therapeutic composition and method for treating skin using centipeda cunninghami extract
JP4495406B2 (en) Sendangusa plant extract-containing composition
KR20090081810A (en) Cosmetic composition containing plant extract
KR100999870B1 (en) Pharmaceutical composition for preventing and treating allergic skin diseases, containing Echo and Elm extract as active ingredients
KR100991399B1 (en) Pharmaceutical composition for the prevention and treatment of allergic skin diseases, which contains Eungseongcho, Geumchocho, Chajeoncho, Elm and upper leaf mixed extract as active ingredients
JP5030366B2 (en) Composition for treatment of allergic diseases
WO2013059942A1 (en) Use of a ginseng extract to prevent and treat alopecia areata
KR20150033797A (en) Pharmaceutical composition for prevention and treatment of atopic skin disease
CN102462753A (en) Traditional Chinese medicine composition for treating cervical vertigo and preparation method thereof
JP5325727B2 (en) Sendangusa plant extract-containing composition
CN101861158A (en) Wound Healing Agent Containing Gacia Seed Extract
CN100488543C (en) Local externally applied itch stopping garlic liniments
CN112569287B (en) Anti-allergy itching-relieving plant composition and preparation method and application thereof
KR101382137B1 (en) A composition comprising the complex extract of corylopsis gotoana and erythronium japonicum
KR100672036B1 (en) Asthma Treatments with Honey Extract
CN108703899B (en) Skin-care massage essential oil
RU2665968C1 (en) Method for obtaining an agent of choleretic, anti-inflammatory and antioxidant activity
CN113069516A (en) Traditional Chinese medicine compound composition for preventing and treating cutaneous pruritus and application thereof
KR100552991B1 (en) Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts
JP2955679B2 (en) Ethanol metabolism promoter
CN110075193A (en) Compound Lantana camara plant extracts and its preparation method and application
JPH0665087A (en) Antipruritic for external use
CN103083376B (en) Can be used for the Rhizoma Ligustici extract for the treatment of rhinitis
CN109568446A (en) A kind of anti-inflammatory antibacterial external application decontamination drug and preparation method thereof of gynaecology
CN108992538A (en) A kind of Chinese medicine preparation and preparation method of hair growth

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090721

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100514

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100519

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100702

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120626

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5030366

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150706

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term